Aethlon subsidiary Exosome supports study for CTE diagnostic test

Aethlon Medical subsidiary Exosome Sciences said today that it plans to support a clinical trial involving retired NFL players to study a biomarker-based diagnostic to detect and monitor chronic traumatic encephalopathy in living people. CTE, a neurodegenerative disease found in American football players and people with a history of repetitive trauma to the head, is traditionally diagnosed after death.

“This study provides researchers an opportunity to potentially change how doctors diagnose CTE, which today can only be diagnosed post-mortem,” principal investigator Kendall Van Keuren-Jensen said in prepared remarks. “Validating plasma exosomal tau as the basis for a non-invasive test to detect and monitor CTE in living individuals will expand significantly the body of clinical data available for analysis and may provide a starting point for early intervention.”

Get the full story at our sister site, Medical Design & Outsourcing.

The post Aethlon subsidiary Exosome supports study for CTE diagnostic test appeared first on MassDevice.

from MassDevice http://ift.tt/2kjkC5K